Related Experiment Videos
Retigabine (ASTA Medica)
1Sultan Qaboos University, College of Science, PO Box 36, Postal Code 123, Ai-Khod, Sultanate of Oman. majek@squ.edu.om
Idrugs : the Investigational Drugs Journal
|July 22, 2005
Summary
Retigabine, a novel potassium channel opener, shows promise for treating epilepsy and complex partial seizures. Clinical trials indicate significant seizure reduction with good tolerability, suggesting a potent and safer alternative to existing treatments.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Retigabine (a carbamic acid ethyl ester) is under development for epilepsy treatment.
- It functions as a selective potassium channel opener.
- Preclinical studies demonstrated anticonvulsive effects and good compatibility.
Purpose of the Study:
- To evaluate the efficacy and safety of retigabine in patients with complex partial seizures and epilepsy.
- To explore its mechanism of action and potential therapeutic applications beyond epilepsy.
Main Methods:
- Phase I, II, and multicenter placebo-controlled clinical trials were conducted.
- Preclinical epilepsy models were used to assess anticonvulsive effects.
- Pharmacokinetic and tolerability studies were performed.
Main Results:
- Phase II trials showed over 50% seizure frequency reduction in 12 of 35 refractory epilepsy patients.
- Phase I trials demonstrated good tolerability and favorable pharmacokinetics.
- Retigabine exhibits greater potency and reduced toxicity compared to valproate.
Conclusions:
- Retigabine is a promising anticonvulsant with a potentially favorable efficacy and safety profile.
- Its mechanism involves selective potassium channel opening, GABA potentiation, and possible modulation of sodium and calcium channels.
- Retigabine also demonstrates neuroprotective activity, suggesting broader therapeutic potential for neurological disorders.